Pharmacotherapy of acute lung injury and the acute respiratory distress syndrome

Journal of Intensive Care Medicine

Volumn 21, Issue 3, 2006, Pages 119-143

  Cepkova, Magda ^a,b   Matthay, Michael A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acute lung injury; Acute respiratory distress syndrome; Pharmacologic therapies; Pulmonary edema

Indexed keywords

2 OXO 4 THIAZOLIDINECARBOXYLIC ACID; ACETYLCYSTEINE; ALBUMIN; ANTICOAGULANT AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; BERACTANT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; DEXAMETHASONE; DIPALMITOYLPHOSPHATIDYLCHOLINE; DROTRECOGIN; GLUCOCORTICOID; ILOPROST; KERATINOCYTE GROWTH FACTOR; KETOCONAZOLE; LISOFYLLINE; LUCINACTANT; LUNG SURFACTANT; LUSUPULTIDE; METHYLPREDNISOLONE; NITRIC OXIDE; PENTOXIFYLLINE; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROSTAGLANDIN E1; SALMETEROL; SURFACTANT PROTEIN A; SURFACTANT PROTEIN B; SURFACTANT PROTEIN C; UNINDEXED DRUG; VASODILATOR AGENT;

ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; ANTIOXIDANT ACTIVITY; ARTIFICIAL VENTILATION; BLOOD CLOTTING; CLINICAL TRIAL; COCHRANE LIBRARY; EXTRACORPOREAL OXYGENATION; HUMAN; LUNG COMPLIANCE; LUNG EDEMA; LUNG GAS EXCHANGE; MEDLINE; MORTALITY; PATHOPHYSIOLOGY; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; REVIEW; SURGICAL PATIENT; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; ANTICOAGULANTS; ANTIOXIDANTS; FIBROBLAST GROWTH FACTOR 7; GLUCOCORTICOIDS; HUMANS; PULMONARY SURFACTANTS; RESPIRATION, ARTIFICIAL; RESPIRATORY DISTRESS SYNDROME, ADULT; VASODILATOR AGENTS;

EID: 33646518813     PISSN: 08850666     EISSN: 15251489     Source Type: Journal    
DOI: 10.1177/0885066606287045     Document Type: Review

References (208)

1. Sackett DL. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest. 1986;89 (2suppl):2S-3S.
2. Kopp R, Kuhlen R, Max M, et al. Evidence-based medicine in the therapy of the acute respiratory distress syndrome. Intensive Care Med. 2002;28:244-255.
3. Pulmonary Artery Catheter Consensus conference: consensus statement. Crit Care Med. 1997;25:910-925.
4. Ashbaugh DG, Bigelow DB, Petty TL, et al. Acute respiratory distress in adults. Lancet. 1967;2:319-323.
5. Petty TL, Ashbaugh DG. The adult respiratory distress syndrome. Clinical features, factors influencing prognosis and principles of management. Chest. 1971;60:233-239.
6. Murray JF, Matthay MA, Luce JM, et al. An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis. 1988;138:720-723.
7. Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994;149:818-824.
8. National Heart and Lung Institute. Task force on problems, research approaches, needs: the lung program. Washington DC: Department of Health, Education and Welfare; 1972; 165-180.
9. Villar J, Slutsky AS. The incidence of the adult respiratory distress syndrome. Am Rev Respir Dis. 1989;140:814-816.
10. Webster NR, Cohen AT, Nunn JF. Adult respiratory distress syndrome - how many cases in the UK? Anaesthesia. 1988;43:923-926.
11. Thomsen GE, Morris AH. Incidence of the adult respiratory distress syndrome in the state of Utah. Am J Respir Crit Care Med. 1995;152:965-971.
12. Luhr OR, Antonsen K, Karlsson M, et al. Incidence and mortality after acute respiratory failure and acute respiratory distress syndrome in Sweden, Denmark, and Iceland. The ARF Study Group. Am J Respir Crit Care Med. 1999;159:1849-1861.
13. Rubenfeld GD, Caldwell E, Peabody E, et al. Incidence and outcomes of acute lung injury. N Engl J Med. 2005;353:1685-1693.
14. Matthay MA, Wiener-Kronish JP. Intact epithelial barrier function is critical for the resolution of alveolar edema in humans. Am Rev Respir Dis. 1990;142:1250-1257.
15. Chapman HA Jr, Bertozzi P, Reilly JJ Jr. Role of enzymes mediating thrombosis and thrombolysis in lung disease. Chest. 1988;93:1256-1263.
16. Idell S, Peters J, James KK, et al. Local abnormalities of coagulation and fibrinolytic pathways that promote alveolar fibrin deposition in the lungs of baboons with diffuse alveolar damage. J Clin Invest. 1989;84:181-193.
17. Esteban A, Fernandez-Segoviano P, Frutos-Vivar F, et al. Comparison of clinical criteria for the acute respiratory distress syndrome with autopsy findings. Ann Intern Med. 2004;141:440-445.
18. Katzenstein AL, Bloor CM, Leibow AA. Diffuse alveolar damage - the role of oxygen, shock, and related factors. A review. Am J Pathol. 1976;85:209-228.
19. Tomashefski JF Jr. Pulmonary pathology of acute respiratory distress syndrome. Clin Chest Med. 2000;21:435-466.
20. Fukuda Y, Ishizaki M, Masuda Y, et al. The role of intraalveolar fibrosis in the process of pulmonary structural remodeling in patients with diffuse alveolar damage. Am J Pathol. 1987;126:171-182.
21. Bachofen M, Weibel ER. Alterations of the gas exchange apparatus in adult respiratory insufficiency associated with septicemia. Am Rev Respir Dis. 1977;116:589-615.
22. Hickling KG, Walsh J, Henderson S, et al. Low mortality rate in adult respiratory distress syndrome using low-volume, pressure-limited ventilation with permissive hypercapnia: a prospective study. Crit Care Med. 1994;22:1568-1578.
23. Hickling KG, Henderson SJ, Jackson R. Low mortality associated with low volume pressure limited ventilation with permissive hypercapnia in severe adult respiratory distress syndrome. Intensive Care Med. 1990;16:372-377.
24. Brochard L, Roudot-Thoraval F, Roupie E, et al. Tidal volume reduction for prevention of ventilator-induced lung injury in acute respiratory distress syndrome. The Multicenter Trial Group on Tidal Volume reduction in ARDS. Am J Respir Crit Care Med. 1998;158:1831-1838.
25. Stewart TE, Meade MO, Cook DJ, et al. Evaluation of a ventilation strategy to prevent barotrauma in patients at high risk for acute respiratory distress syndrome. Pressure- and Volume-Limited Ventilation Strategy Group. N Engl J Med. 1998;338:355-361.
26. Amato MB, Barbas CS, Medeiros DM, et al. Effect of a protective- ventilation strategy on mortality in the acute respiratory distress syndrome. N Engl J Med. 1998;338:347-354.
27. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med. 2000;342:1301-1308.
28. Weinert CR, Gross CR, Marinelli WA. Impact of randomized trial results on acute lung injury ventilator therapy in teaching hospitals. Am J Respir Crit Care Med. 2003;167:1304-1309.
29. Brower RG, Lanken PN, MacIntyre N, et al. Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. N Engl J Med. 2004;351:327-336.
30. Guerin C, Gaillard S, Lemasson S, et al. Effects of systematic prone positioning in hypoxemic acute respiratory failure: a randomized controlled trial. JAMA. 2004;292:2379-2387.
31. Curley MA, Thompson JE, Arnold JH. The effects of early and repeated prone positioning in pediatric patients with acute lung injury. Chest. 2000;118:156-163.
32. Curley MA Hibbard PL, Fineman LD, et al. Effect of prone positioning on clinical outcomes in children with acute lung injury: a randomized controlled trial. JAMA. 2005;294:229-237.
33. Simmons RS, Berdine GG, Seidenfeld JJ, et al. Fluid balance and the adult respiratory distress syndrome. Am Rev Respir Dis. 1987;135:924-929.
34. Eisenberg PR, Hansbrough JR, Anderson D, et al. A prospective study of lung water measurements during patient management in an intensive care unit. Am Rev Respir Dis. 1987;136:662-668.
35. Humphrey H, Hall J, Sznajder I, et al. Improved survival in ARDS patients associated with a reduction in pulmonary capillary wedge pressure. Chest. 1990;97:1176-1180.
36. Mitchell JP, Schuller D, Calandrino FS, et al. Improved outcome based on fluid management in critically ill patients requiring pulmonary artery catheterization. Am Rev Respir Dis. 1992;45:990-998.
37. Yu M, Levy MM, Smith P, et al. Effect of maximizing oxygen delivery on morbidity and mortality rates in critically ill patients: a prospective, randomized, controlled study. Crit Care Med. 1993;21:830-838.
38. Tuchschmidt J, Fried J, Astiz M, et al. Elevation of cardiac output and oxygen delivery improves outcome in septic shock. Chest. 1992;102:216-220.
39. Hayes MA, Timmins AC, Yau EH, et al. Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med. 1994;330:1717-1722.
40. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345:1368-1377.
41. Weaver TE, Whitsett JA. Function and regulation of expression of pulmonary surfactant-associated proteins. Biochem J. 1991;273:249-264.
42. Possmayer F. The role of surfactant-associated proteins. Am Rev Respir Dis. 1990;142:749-752.
43. Hoekstra RE, Jackson JC, Myers TF, et al. Improved neonatal survival following multiple doses of bovine surfactant in very premature neonates at risk for respiratory distress syndrome. Pediatrics. 1991;88:10-18.
44. Long W, Corbet A, Cotton R, et al. A controlled trial of synthetic surfactant in infants weighing 1250 g or more with respiratory distress syndrome. The American Exosurf Neonatal Study Group I, and the Canadian Exosurf Neonatal Study Group. N Engl J Med. 1991;325:1696-1703.
45. Liechty EA, Donovan E, Purohit D, et al. Reduction of neonatal mortality after multiple doses of bovine surfactant in low birth weight neonates with respiratory distress syndrome. Pediatrics. 1991;88:19-28.
46. Corbet AJ, Long WA, Murphy DJ, et al. Reduced mortality in small premature infants treated at birth with a single dose of synthetic surfactant. J Paediatr Child Health. 1991;27:245-249.
47. Corbet A, Bucciarelli R, Goldman S, et al. Decreased mortality rate among small premature infants treated at birth with a single dose of synthetic surfactant: a multicenter controlled trial. American Exosurf Pediatric Study Group 1. J Pediatr. 1991;118:277-284.
48. Schmidt R, Meier U, Yabut-Perez M, et al. Alteration of fatty acid profiles in different pulmonary surfactant phospholipids in acute respiratory distress syndrome and severe pneumonia. Am J Respir Crit Care Med. 2001;163:95-100.
49. Pison U, Seeger W, Buchhorn R, et al. Surfactant abnormalities in patients with respiratory failure after multiple trauma. Am Rev Respir Dis. 1989;140:1033-1039.
50. Hallman M, Spragg R, Harrell JH, et al. Evidence of lung surfactant abnormality in respiratory failure. Study of bronchoalveolar lavage phospholipids, surface activity, phospholipase activity, and plasma myoinositol. J Clin Invest. 1982;70:673-683.
51. Lewis JF, Jobe AH. Surfactant and the adult respiratory distress syndrome. Am Rev Respir Dis. 1993;147:218-233.
52. Albert RK, Lakshminarayan S, Hildebrandt J, et al. Increased surface tension favors pulmonary edema formation in anesthetized dogs' lungs. J Clin Invest. 1979;63:1015-1018.
53. Richman PS, Spragg RG, Robertson B, et al. The adult respiratory distress syndrome: first trials with surfactant replacement. Eur Respir J Suppl. 1989;3:109s-111s.
54. Reines HD, Silverman H, Hurst J, et al. Effects of two concentrations of nebulized surfactant (Exosurf) in sepsis-induced adult respiratory distress syndrome (ARDS). Crit Care Med. 1992;20:S61.
55. Spragg RG, Gilliard N, Richman P, et al. Acute effects of a single dose of porcine surfactant on patients with the adult respiratory distress syndrome. Chest. 1994;105:195-202.
56. Weg JG, Balk RA, Tharratt RS, et al. Safety and potential efficacy of an aerosolized surfactant in human sepsis-induced adult respiratory distress syndrome. JAMA. 1994;272:1433-1438.
57. Anzueto A, Baughman RP, Guntupalli KK, et al. Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. Exosurf Acute Respiratory Distress Syndrome Sepsis Study Group. N Engl J Med. 1996;334:1417-1421.
58. Walmrath D, Gunther A, Ghofrani HA, et al. Bronchoscopic surfactant administration in patients with severe adult respiratory distress syndrome and sepsis. Am J Respir Crit Care Med. 1996;154:57-62.
59. Walmrath D, Grimminger F, Pappert D, et al. Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact on gas exchange and haemodynamics. Eur Respir J. 2002;19:805-810.
60. Wiswell TE, Smith RM, Katz LB, et al. Bronchopulmonary segmental lavage with Surfaxin (KL(4)-surfactant) for acute respiratory distress syndrome. Am J Respir Crit Care Med. 1999;160:1188-1195.
61. Spragg RG, Lewis JF, Wurst W, et al. Treatment of acute respiratory distress syndrome with recombinant surfactant protein C surfactant. Am J Respir Crit Care Med. 2003;167:1562-1566.
62. Gregory TJ, Steinberg KP, Spragg R, et al. Bovine surfactant therapy for patients with acute respiratory distress syndrome. Am J Respir Crit Care Med. 1997;155:1309-1315.
63. Spragg RG, Lewis JF, Walmrath HD, et al. Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome. N Engl J Med. 2004;351:884-892.
64. Baudouin SV. Exogenous surfactant replacement in ARDS - one day, someday, or never? N Engl J Med. 2004;351:853-855.
65. Willson DF, Thomas NJ, Markovitz BP, et al. Effect of exogenous surfactant (calfactant) in pediatric acute lung injury: a randomized controlled trial. JAMA. 2005;293:470-476.
66. Kaisers U, Busch T, Deja M, et al. Selective pulmonary vasodilation in acute respiratory distress syndrome. Crit Care Med. 2003;31:S337-342.
67. Jardin F, Gurdjian F, Fouilladieu JL, et al. Pulmonary and systemic haemodynamic disorders in the adult respiratory distress syndrome. Intensive Care Med. 1979;5:127-133.
68. Villar J, Blazquez MA, Lubillo S, et al. Pulmonary hypertension in acute respiratory failure. Crit Care Med. 1989;7:523-526.
69. Squara P, Dhainaut JF, Artigas A, et al. Hemodynamic profile in severe ARDS: results of the European Collaborative ARDS Study. Intensive Care Med. 1998;24:1018-1028.
70. Rimar S, Gillis CN. Selective pulmonary vasodilation by inhaled nitric oxide is due to hemoglobin inactivation. Circulation. 1993;88:2884-2887.
71. Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, et al. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet. 1991;338:1173-1174.
72. Frostell C, Fratacci MD, Wain JC, et al. Inhaled nitric oxide. A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. Circulation. 1991;83:2038-2047.
73. Rossaint R, Falke KJ, Lopez F, et al. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med. 1993;328:399-405.
74. Michael JR, Barton RG, Saffle JR, et al. Inhaled nitric oxide versus conventional therapy: effect on oxygenation in ARDS. Am J Respir Crit Care Med. 1998;157:1372-1380.
75. Troncy E, Collet JP, Shapiro S, et al. Inhaled nitric oxide in acute respiratory distress syndrome: a pilot randomized controlled study. Am J Respir Crit Care Med. 1998;157:1483-1488.
76. Dellinger RP, Zimmerman JL, Taylor RW, et al. Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial. Inhaled Nitric Oxide in ARDS Study Group. Crit Care Med. 1998;26:15-23.
77. Lundin S, Mang H, Smithies M, et al. Inhalation of nitric oxide in acute lung injury: results of a European multicentre study. The European Study Group of Inhaled Nitric Oxide. Intensive Care Med. 1999;25:911-919.
78. Taylor RW, Zimmerman JL, Dellinger RP, et al. Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial. JAMA. 2004;291:1603-1609.
79. Walmrath D, Schneider T, Pilch J, et al. Aerosolised prostacyclin in adult respiratory distress syndrome. Lancet. 1993;342:961-962.
80. Zwissler B, Kemming G, Habler O, et al. Inhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult respiratory distress syndrome. Am J Respir Crit Care Med. 1996;154:1671-1677.
81. Walmrath D, Schneider T, Schermuly R, et al. Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome. Am J Respir Crit Care Med. 1996;153:991-996.
82. Van Heerden PV, Blythe D, Webb SA. Inhaled aerosolized prostacyclin and nitric oxide as selective pulmonary vasodilators in ARDS - a pilot study. Anaesth Intensive Care. 1996;24:564-568.
83. Pappert D, Busch T, Gerlach H, et al. Aerosolized prostacyclin versus inhaled nitric oxide in children with severe acute respiratory distress syndrome. Anesthesiology. 1995;82:1507-1511.
84. Mikawa K, Akamatsu H, Maekawa N, et al. Inhibitory effect of prostaglandin E1 on human neutrophil function. Prostaglandins Leukot Essent Fatty Acids. 1994;51:287-291.
85. Putensen C, Hormann C, Kleinsasser A, et al. Cardiopulmonary effects of aerosolized prostaglandin E1 and nitric oxide inhalation in patients with acute respiratory distress syndrome. Am J Respir Crit Care Med. 1998;157:1743-1747.
86. Melot C, Lejeune P, Leeman M, et al. Prostaglandin E1 in the adult respiratory distress syndrome. Benefit for pulmonary hypertension and cost for pulmonary gas exchange. Am Rev Respir Dis. 1989;139:106-110.
87. Zhang H, Benlabed M, Spapen H, et al. Prostaglandin E1 increases oxygen extraction capabilities in experimental sepsis. J Surg Res. 1994;57:470-479.
88. Groeneveld AB, Vermeij CG, Nauta JJ, et al. Vasodilating prostaglandin E1 decreases critical oxygen delivery by increasing critical oxygen extraction in anesthetized pigs. Circ Shock. 1993;39:253-262.
89. Grant MM, Burnett CM, Fein AM. Effect of prostaglandin E1 infusion on leukocyte traffic and fibrosis in acute lung injury induced by bleomycin in hamsters. Crit Care Med. 1991;19:211-217.
90. Yamanaka K, Saluja AK, Brown GE, et al. Protective effects of prostaglandin E1 on acute lung injury of caerulein-induced acute pancreatitis in rats. Am J Physiol. 1997;272:G23-G30.
91. Holcroft JW, Vassar MJ, Weber CJ. Prostaglandin E1 and survival in patients with the adult respiratory distress syndrome. A prospective trial. Ann Surg. 1986;203:371-378.
92. Slotman GJ, Kerstein MD, Bone RC, et al. The effects of prostaglandin E1 on non-pulmonary organ function during clinical acute respiratory failure. The Prostaglandin E1 Study Group. J Trauma. 1992;32:480-488; discussion 488-489
93. Bone RC, Slotman G, Maunder R, et al. Randomized double-blind, multicenter study of prostaglandin E1 in patients with the adult respiratory distress syndrome. Prostaglandin E1 Study Group. Chest. 1989;96:114-119.
94. Rossignon MD, Khayat D, Royer C, et al. Functional and metabolic activity of polymorphonuclear leukocytes from patients with adult respiratory distress syndrome: results of a randomized double-blind placebo-controlled study on the activity of prostaglandin E1. Anesthesiology. 1990;72:276-281.
95. Eierman DF, Yagami M, Erme SM, et al. Endogenously opsonized particles divert prostanoid action from lethal to protective in models of experimental endotoxemia. Proc Natl Acad Sci USA. 1995;92:2815-2819.
96. Abraham E, Park YC, Covington P, et al. Liposomal prostaglandin E1 in acute respiratory distress syndrome: a placebo-controlled, randomized, double-blind, multicenter clinical trial. Crit Care Med. 1996;24:10-15.
97. Abraham E, Baughman R, Fletcher E, et al. Liposomal prostaglandin E1 (TLC C-53) in acute respiratory distress syndrome: a controlled, randomized, double-blind, multicenter clinical trial. TLC C-53 ARDS Study Group. Crit Care Med. 1999;27:1478-1485.
98. Vincent JL, Brase R, Santman F, et al. A multi-centre, double-blind, placebo-controlled study of liposomal prostaglandin E1 (TLC C-53) in patients with acute respiratory distress syndrome. Intensive Care Med. 2001;27:1578-1583.
99. Wiegers GJ, Reul JM. Induction of cytokine receptors by glucocorticoids: functional and pathological significance. Trends Pharmacol Sci. 1998;19:317-321.
100. Newton R. Molecular mechanisms of glucocorticoid action: what is important? Thorax. 2000;55:603-613.
101. Saatcioglu F, Claret EX, Karin M. Negative transcriptional regulation by nuclear receptors. Semin Cancer Biol. 1994;5:347-359.
102. Ray A, Prefontaine KE. Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor. Proc Natl Acad Sci U S A. 1994;91:752-756.
103. Yang-Yen HF, Chambard JC, Sun YL, et al. Transcriptional interference between c-Jun and the glucocorticoid receptor: mutual inhibition of DNA binding due to direct protein-protein interaction. Cell. 1990;62:1205-1215.
104. van de Stolpe A, Caldenhoven E, Raaijmakers JA, et al. Glucocorticoid-mediated repression of intercellular adhesion molecule-1 expression in human monocytic and bronchial epithelial cell lines. Am J Respir Cell Mol Biol. 1993;8:340-347.
105. Jantz MA, Sahn SA. Corticosteroids in acute respiratory failure. Am J Respir Crit Care Med. 1999;60:1079-1100.
106. Thompson BT. Glucocorticoids and acute lung injury. Crit Care Med. 2003;31:S253-S257.
107. Dik WA, McAnulty RJ, Versnel MA, et al. Short course dexamethasone treatment following injury inhibits bleomycin induced fibrosis in rats. Thorax. 2003;58:765-771.
108. Weigelt JA, Norcross JF, Borman KR, et al. Early steroid therapy for respiratory failure. Arch Surg. 1985;120:536-540.
109. Sprung CL, Caralis PV, Marcial EH, et al. The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. N Engl J Med. 1984;311:1137-1143.
110. Bone RC, Fisher CJ Jr, Clemmer TP, et al. Early methylprednisolone treatment for septic syndrome and the adult respiratory distress syndrome. Chest. 1987;92:1032-1036.
111. Luce JM, Montgomery AB, Marks JD, et al. Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am Rev Respir Dis. 1988;138:62-68.
112. Bernard GR, Luce JM, Sprung CL, et al. High-dose corticosteroids in patients with the adult respiratory distress syndrome. N Engl J Med. 1987;317:1565-1570.
113. Ashbaugh DG, Maier RV. Idiopathic pulmonary fibrosis in adult respiratory distress syndrome. Diagnosis and treatment. Arch Surg. 1985;120:530-535.
114. Hooper RG, Kearl RA. Established ARDS treated with a sustained course of adrenocortical steroids. Chest. 1990;97:138-143.
115. Hooper RG, Kearl RA. Established adult respiratory distress syndrome successfully treated with corticosteroids. South Med J. 1996;89:359-364.
116. Meduri GU, Belenchia JM, Estes RJ, et al. Fibroproliferative phase of ARDS. Clinical findings and effects of corticosteroids. Chest. 1991;100:943-952.
117. Meduri GU, Chinn AJ, Leeper KV, et al. Corticosteroid rescue treatment of progressive fibroproliferation in late ARDS. Patterns of response and predictors of outcome. Chest. 1994;105:1516-1527.
118. Meduri GU, Headley AS, Golden E, et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. JAMA. 1998;280:159-165.
119. Lelcuk S, Huval WV, Valeri CR, et al. Inhibition of ischemia-induced thromboxane synthesis in man. J Trauma. 1984;24:393-396.
120. Williams JG, Maier RV. Ketoconazole inhibits alveolar macrophage production of inflammatory mediators involved in acute lung injury (adult respiratory distress syndrome). Surgery. 1992;112:270-277.
121. Yu M, Tomasa G. A double-blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome. Crit Care Med. 1993;21:1635-1642.
122. Slotman GJ, Burchard KW, D'Arezzo A, et al. Ketoconazole prevents acute respiratory failure in critically ill surgical patients. J Trauma. 1988;28:648-654.
123. Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. The ARDS Network. JAMA 2000;283:1995-2002.
124. Mandell GL. ARDS, neutrophils, and pentoxifylline. Am Rev Respir Dis. 1988;138:1103-1105.
125. Welsh CH, Lien D, Worthen GS, et al. Pentoxifylline decreases endotoxin-induced pulmonary neutrophil sequestration and extravascular protein accumulation in the dog. Am Rev Respir Dis. 1988;138:1106-1114.
126. Seear MD, Hannam VL, Kaapa P, et al. Effect of pentoxifylline on hemodynamics, alveolar fluid reabsorption, and pulmonary edema in a model of acute lung injury. Am Rev Respir Dis. 1990;142:1083-1087.
127. Kudoh I, Ohtake M, Nishizawa H, et al. The effect of pentoxifylline on acid-induced alveolar epithelial injury. Anesthesiology. 1995;82:531-541.
128. Montravers P, Fagon JY, Gilbert C, et al. Pilot study of cardiopulmonary risk from pentoxifylline in adult respiratory distress syndrome. Chest. 1993;103:1017-1022.
129. Hasegawa N, Oka Y, Nakayama M, et al. The effects of post-treatment with lisofylline, a phosphatidic acid generation inhibitor, on sepsis-induced acute lung injury in pigs. Am J Respir Crit Care Med. 1997;155:928-936.
130. Rice GC, Rosen J, Weeks R, et al. CT-1501R selectively inhibits induced inflammatory monokines in human whole blood ex vivo. Shock. 1994;1:254-266.
131. Guidot DM, Bursten SL, Rice GC, et al. Modulating phosphatidic acid metabolism decreases oxidative injury in rat lungs. Am J Physiol. 1997;273:L957-L966.
132. Bursten SL, Federighi DA, Parsons P, et al. An increase in serum C18 unsaturated free fatty acids as a predictor of the development of acute respiratory distress syndrome. Crit Care Med. 1996;24:1129-1136.
133. Rice GC, Brown PA, Nelson RJ, et al. Protection from endotoxic shock in mice by pharmacologic inhibition of phosphatidic acid. Proc Natl Acad Sci U S A. 1994;91:3857-3861.
134. Randomized, placebo-controlled trial of lisofylline for early treatment of acute lung injury and acute respiratory distress syndrome. Crit Care Med. 2002;30:1-6.
135. Baird BR, Cheronis JC, Sandhaus RA, et al. O2 metabolites and neutrophil elastase synergistically cause edematous injury in isolated rat lungs. J Appl Physiol. 1986;61:2224-2229.
136. Pacht ER, Timerman AP, Lykens MG, et al. Deficiency of alveolar fluid glutathione in patients with sepsis and the adult respiratory distress syndrome. Chest. 1991;100:1397-1403.
137. Bunnell E, Pacht ER. Oxidized glutathione is increased in the alveolar fluid of patients with the adult respiratory distress syndrome. Am Rev Respir Dis. 1993;148:1174-1178.
138. Quinlan GJ, Lamb NJ, Tilley R, et al. Plasma hypoxanthine levels in ARDS: implications for oxidative stress, morbidity, and mortality. Am J Respir Crit Care Med. 1997;155:479-484.
139. Bernard GR. N-acetylcysteine in experimental and clinical acute lung injury. Am J Med. 1991;91:54S-59S.
140. Bernard GR, Lucht WD, Niedermeyer ME, et al. Effect of N-acetylcysteine on the pulmonary response to endotoxin in the awake sheep and upon in vitro granulocyte function. J Clin Invest. 1984;73:1772-1784.
141. Jepsen S, Herlevsen P, Knudsen P, et al. Antioxidant treatment with N-acetylcysteine during adult respiratory distress syndrome: a prospective, randomized, placebo-controlled study. Crit Care Med. 1992;20:918-923.
142. Suter PM, Domenighetti G, Schaller MD, et al. N-acetylcysteine enhances recovery from acute lung injury in man. A randomized, double-blind, placebo-controlled clinical study. Chest. 1994;105:190-194.
143. Domenighetti G, Suter PM, Schaller MD, et al. Treatment with N-acetylcysteine during acute respiratory distress syndrome: a randomized, double-blind, placebo-controlled clinical study. J Crit Care. 1997;12:177-182.
144. Bernard GR, Wheeler AP, Arons MM, et al. A trial of antioxidants N-acetylcysteine and procysteine in ARDS. The Antioxidant in ARDS Study Group. Chest. 1997;112:164-172.
145. Walsh TS, Lee A. N-acetylcysteine administration in the critically ill. Intensive Care Med. 1999;25:432-434.
146. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med. 2000;342:1334-1349.
147. Moran LK, Gutteridge JM, Quinlan GJ. Thiols in cellular redox signalling and control. Curr Med Chem. 2001;8:763-772.
148. Quinlan GJ, Evans TW, Gutteridge JM. Oxidative damage to plasma proteins in adult respiratory distress syndrome. Free Radic Res. 1994;20:289-298.
149. Quinlan GJ, Margarson MP, Mumby S, et al. Administration of albumin to patients with sepsis syndrome: a possible beneficial role in plasma thiol repletion. Clin Sci (Lond). 1998;95:459-465.
150. Quinlan GJ, Mumby S, Martin GS, et al. Albumin influences total plasma antioxidant capacity favorably in patients with acute lung injury. Crit Care Med. 2004;32:755-759.
151. Finfer S, Norton R, Bellomo R, et al. The SAFE study: saline vs. albumin for fluid resuscitation in the critically ill. Vox Sang. 2004;87(suppl 2):123-131.
152. Martin GS, Moss M, Wheeler AP, et al. A randomized, controlled trial of furosemide with or without albumin in hypoproteinemic patients with acute lung injury. Crit Care Med. 2005;33:1681-1687.
153. Greene R, Zapol WM, Snider MT, et al. Early bedside detection of pulmonary vascular occlusion during acute respiratory failure. Am Rev Respir Dis. 1981;124:593-601.
154. Tomashefski JF Jr, Davies P, Boggis C, et al. The pulmonary vascular lesions of the adult respiratory distress syndrome. Am J Pathol. 1983;112:112-126.
155. Nuckton TJ, Alonso JA, Kallet RH, et al. Pulmonary dead-space fraction as a risk factor for death in the acute respiratory distress syndrome. N Engl J Med. 2002;346:1281-1286.
156. Creasey AA, Chang AC, Feigen L, et al. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest. 1993;91:2850-2860.
157. Welty-Wolf KE, Carraway MS, Miller DL, et al. Coagulation blockade prevents sepsis-induced respiratory and renal failure in baboons. Am J Respir Crit Care Med. 2001;164:1988-1996.
158. Miller DL, Welty-Wolf K, Carraway MS, et al. Extrinsic coagulation blockade attenuates lung injury and proinflammatory cytokine release after intratracheal lipopolysaccharide. Am J Respir Cell Mol Biol. 2002;26:650-658.
159. Abraham E, Reinhart K, Svoboda P, et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med. 2001;29:2081-2089.
160. Abraham E, Reinhart K, Opal S, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003;290:238-247.
161. Fourrier F, Chopin C, Goudemand J, et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest. 1992;101:816-823.
162. Fourrier F, Chopin C, Huart JJ, et al. Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest. 1993;104:882-888.
163. Baudo F, Caimi TM, de Cataldo F, et al. Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. Intensive Care Med. 1998;24:336-342.
164. Eisele B, Lamy M, Thijs LG, et al. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med. 1998;4:663-672.
165. Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA. 2001;286:1869-1878.
166. Tasaki O, Mozingo DW, Dubick MA, et al. Effects of heparin and lisofylline on pulmonary function after smoke inhalation injury in an ovine model. Crit Care Med. 2002;30:637-643.
167. Uchiba M, Okajima K, Murakami K, et al. Attenuation of endotoxin-induced pulmonary vascular injury by antithrombin III. Am J Physiol. 1996;270:L921-L930.
168. Abubakar K, Schmidt B, Monkman S, et al. Heparin improves gas exchange during experimental acute lung injury in newborn piglets. Am J Respir Crit Care Med. 1998;158:1620-1625.
169. Malik AB, van der Zee H. Time course of pulmonary vascular response to microembolization. J Appl Physiol. 1977;43:51-58.
170. Davidson BL, Geerts WH, Lensing AW. Low-dose heparin for severe sepsis. N Engl J Med. 2002;347:1036-1037.
171. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699-709.
172. Opal SM. Unintended bias, clinical trial results, and the heparin post hoc crossover fallacy Crit Care Med. 2004;32:874-875.
173. Ware LB, Fang X, Matthay MA. Protein C and thrombomodulin in human acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2003;285:L514-L521.
174. Prabhakaran P, Ware LB, White KE, et al. Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2003;285:L20-L28.
175. van der Poll T, Levi M, Nick JA, et al. Activated protein C inhibits local coagulation after intrapulmonary delivery of endotoxin in humans. Am J Respir Crit Care Med. 2005;171:1125-1128.
176. Ware LB, Matthay MA. Alveolar fluid clearance is impaired in the majority of patients with acute lung injury and the acute respiratory distress syndrome. Am J Respir Crit Care Med. 2001;163:1376-1383.
177. Matthay MA, Folkesson HG, Clerici C. Lung epithelial fluid transport and the resolution of pulmonary edema. Physiol Rev. 2002;82:569-600.
178. Crandall ED, Matthay MA. Alveolar epithelial transport. Basic science to clinical medicine. Am J Respir Crit Care Med. 2001;163:1021-1029.
179. Berthiaume Y, Staub NC, Matthay MA. Beta-adrenergic agonists increase lung liquid clearance in anesthetized sheep. J Clin Invest. 1987;79:335-343.
180. Berthiaume Y, Broaddus VC, Gropper MA, et al. Alveolar liquid and protein clearance from normal dog lungs. J Appl Physiol. 1988;65:585-593.
181. Sakuma T, Okaniwa G, Nakada T, et al. Alveolar fluid clearance in the resected human lung. Am J Respir Crit Care Med. 1994;150:305-310.
182. Sakuma T, Suzuki S, Usuda K, et al. Preservation of alveolar epithelial fluid transport mechanisms in rewarmed human lung after severe hypothermia. J Appl Physiol. 1996;80:1681-1686.
183. Sakuma T, Folkesson HG, Suzuki S, et al. Beta-adrenergic agonist stimulated alveolar fluid clearance in ex vivo human and rat lungs. Am J Respir Crit Care Med. 1997;155:506-512.
184. Lasnier JM, Wangensteen OD, Schmitz LS, et al. Terbutaline stimulates alveolar fluid resorption in hyperoxic lung injury. J Appl Physiol. 1996;81:1723-1729.
185. Saldias FJ, Lecuona E, Comellas AP, et al. Beta-adrenergic stimulation restores rat lung ability to clear edema in ventilator-associated lung injury. Am J Respir Crit Care Med. 2000;162:282-287.
186. Saldias FJ, Comellas A, Ridge KM, et al. Isoproterenol improves ability of lung to clear edema in rats exposed to hyperoxia. J Appl Physiol. 1999;87:30-35.
187. Garat C, Meignan M, Matthay MA, et al. Alveolar epithelial fluid clearance mechanisms are intact after moderate hyperoxic lung injury in rats. Chest. 1997;111:1381-1388.
188. McAuley DF, Frank JA, Fang X, et al. Clinically relevant concentrations of beta2-adrenergic agonists stimulate maximal cyclic adenosine monophosphate-dependent airspace fluid clearance and decrease pulmonary edema in experimental acid-induced lung injury. Crit Care Med. 2004;32:1470-1476.
189. Minnear FL, DeMichele MA, Moon DG, et al. Isoproterenol reduces thrombin-induced pulmonary endothelial permeability in vitro. Am J Physiol. 1989;257:H1613-H1623.
190. Minnear FL, DeMichele MA, Leonhardt S, et al. Isoproterenol antagonizes endothelial permeability induced by thrombin and thrombin receptor peptide. J Appl Physiol. 1993;75:1171-1179.
191. Khimenko PL, Barnard JW, Moore TM, et al. Vascular permeability and epithelial transport effects on lung edema formation in ischemia and reperfusion. J Appl Physiol. 1994;77:1116-1121.
192. Zhang H, Kim YK, Govindarajan A, et al. Effect of adrenoreceptors on endotoxin-induced cytokines and lipid peroxidation in lung explants. Am J Respir Crit Care Med. 1999;160:1703-1710.
193. Wright PE, Carmichael LC, Bernard GR. Effect of bronchodilators on lung mechanics in the acute respiratory distress syndrome (ARDS). Chest. 1994;106:1517-1523.
194. Sartori C, Allemann Y, Duplain H, et al. Salmeterol for the prevention of high-altitude pulmonary edema. N Engl J Med. 2002;346:1631-1636.
195. Ware LB, Matthay MA. Keratinocyte and hepatocyte growth factors in the lung: roles in lung development, inflammation, and repair. Am J Physiol Lung Cell Mol Physiol. 2002;282:L924-L940.
196. Barton SP, Marks R. Changes in suspensions of human keratinocytes due to trypsin. Arch Dermatol Res. 1981;271:245-257.
197. Adamson IY, Bakowska J. Relationship of keratinocyte growth factor and hepatocyte growth factor levels in rat lung lavage fluid to epithelial cell regeneration after bleomycin. Am J Pathol. 1999;155:949-954.
198. Panos RJ, Bak PM, Simonet WS, et al. Intratracheal instillation of keratinocyte growth factor decreases hyperoxia-induced mortality in rats. J Clin Invest. 1995;96:2026-2033.
199. Yi ES, Salgado M, Williams S, et al. Keratinocyte growth factor decreases pulmonary edema, transforming growth factor-beta and platelet-derived growth factor-BB expression, and alveolar type II cell loss in bleomycin-induced lung injury. Inflammation. 1998;22:315-325.
200. Yano T, Deterding RR, Simonet WS, et al. Keratinocyte growth factor reduces lung damage due to acid instillation in rats. Am J Respir Cell Mol Biol. 1996;15:433-442.
201. Sugahara K, Iyama K, Kuroda MJ, et al. Double intratracheal instillation of keratinocyte growth factor prevents bleomycininduced lung fibrosis in rats. J Pathol. 1998;186:90-98.
202. Mason CM, Guery BP, Summer WR, et al. Keratinocyte growth factor attenuates lung leak induced by alpha-naphthylthiourea in rats. Crit Care Med. 1996;24:925-931.
203. Guery BP, Mason CM, Dobard EP, et al. Keratinocyte growth factor increases transalveolar sodium reabsorption in normal and injured rat lungs. Am J Respir Crit Care Med. 1997;155:1777-1784.
204. Panoskaltsis-Mortari A, Lacey DL, Vallera DA, et al. Keratinocyte growth factor administered before conditioning ameliorates graft-versus-host disease after allogeneic bone marrow transplantation in mice. Blood. 1998;92:3960-3967.
205. Chen L, Brizel DM, Rabbani ZN, et al. The protective effect of recombinant human keratinocyte growth factor on radiation-induced pulmonary toxicity in rats. Int J Radiat Oncol Biol Phys. 2004;0:1520-1529.
206. Meropol NJ, Somer RA, Gutheil J, et al. Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. J Clin Oncol. 2003;21:1452-1458.
207. Shoemaker WC, Appel PL. Effects of prostaglandin E1 in adult respiratory distress syndrome. Surgery. 1986;99:275-283.
208. Matthay MA, Zimmerman GA. Acute lung injury and the acute respiratory distress syndrome; four decades of inquiry into pathogenesis and rational management. Am J Respir Cell Mol Biol. 2005;33:319-327.